Welcome to our dedicated page for ACADIA PHARMACEUTICALS SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acadia Pharmaceuticals Inc. filings document the regulatory record for a commercial biopharmaceutical company focused on neurological and rare diseases. Recent Form 8-K reports furnish quarterly and annual operating results, product-sales disclosures for NUPLAZID and DAYBUE, corporate presentations and Regulation FD materials, and updates tied to research-and-development leadership.
Proxy and governance filings describe board composition, committee service, director compensation, executive compensation, equity-incentive awards and annual meeting matters. The filings also record board appointments and resignations, non-employee director compensation under equity plans, and other material-event disclosures affecting Acadia’s governance and capital structure.
ACADIA Pharmaceuticals’ EVP and CFO Mark C. Schneyer exercised stock options covering 20,141 shares of common stock at an exercise price of $17.84 per share on August 5–6, 2026.
He then sold 20,141 shares in market transactions at prices around $29 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025.
State Street Corporation has filed as a significant institutional holder of ACADIA PHARMACEUTICALS INC common stock. The filing reports that State Street beneficially owns 9,076,212 shares of common stock, representing 5.3% of the class.
State Street reports no sole voting or dispositive power, but shared voting power over 8,679,785 shares and shared dispositive power over 9,076,212 shares. Subsidiaries involved include SSGA Funds Management, Inc. and several State Street Global Advisors entities, indicating the holdings are managed across affiliated investment advisers.
Acadia Pharmaceuticals reported GAAP total revenues of $308 million for the quarter ended June 30, 2026, up 16% from $265 million a year earlier and 17% versus non-GAAP adjusted revenues. NUPLAZID net sales were $183 million, up 9% year-over-year and 10% on a non-GAAP adjusted basis, while DAYBUE net sales reached $125 million, up 30%. Quarterly net income was $32 million, or $0.18 per diluted share, and cash, cash equivalents and investment securities totaled $956 million.
The company raised its 2026 total revenue guidance to $1.24–$1.30 billion, increased DAYBUE sales guidance to $480–$510 million, and lowered expected R&D expenses to $355–$380 million. Acadia highlighted progress for remlifanserin in Alzheimer’s disease psychosis, including FDA Fast Track designation and ongoing RADIANT Phase 2/3 work, and noted a CHMP positive opinion recommending EU marketing authorization for DAYBU in Rett syndrome.
ACADIA Pharmaceuticals executive Elizabeth H.Z. Thompson, EVP and Head of Research & Development, reported vesting and conversion of 32,272 restricted stock units into common stock on July 29, 2026. To cover withholding taxes on this vesting, she sold 16,558 shares of common stock on July 30, 2026 at prices around $26.13–$26.17 per share in mandatory transactions intended to comply with Rule 10b5-1(c) requirements. The RSU award vests 50% on July 29, 2026 and 25% on each of July 29, 2027 and July 29, 2028.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara sold 11,421 shares of common stock in an open-market transaction at a weighted average price of $26.0846 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, and Kihara now holds 13,088 shares directly.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
ACADIA PHARMACEUTICALS INC reported equity compensation grants linked to Baker-related entities and funds. The filing shows awards connected to board service by Julian C. Baker and Dr. Stephen R. Biggar, where the Baker funds have an indirect pecuniary interest.
The grants include a total of 18,622 restricted stock units and 32,008 non-qualified stock options, reported for the funds because each fund has an indirect pecuniary interest in these securities. The stock options carry a strike price of $21.66, vest in four equal quarterly installments beginning on May 29, 2026, and expire on May 28, 2036. The adviser has voting and dispositive power over the options, RSUs, and any common stock issued from them, while Julian C. Baker, Felix J. Baker, Baker Bros. Advisors LP, and its general partner disclaim beneficial ownership except to the extent of their pecuniary interest.
ACADIA Pharmaceuticals director Edmund Harrigan reported compensation-related equity activity, not open-market trading. On May 29, 2026, he exercised restricted stock units into 8,107 shares of common stock, bringing his direct common stock holdings to 43,148 shares.
He also received new awards on the same date: 9,311 restricted stock units, each representing a right to one share of common stock, and 16,004 director stock options with a $21.66 exercise price expiring on May 28, 2036. The new RSUs and options vest over roughly one year or until the next annual stockholders’ meeting, aligning his compensation with shareholder outcomes.